- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr William "Andy" Nish on Considering Adherence When Prescribing Biologics to Patients With Asthma
Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.
William "Andy" Nish, MD, is a medical director and provider with a specialty in allergy and immunology at Northeast Georgia Physicians Group in Gainesville, Georgia.
Transcript:
If nonadherence with inhaled corticosteroids has been a factor for the patient, should that influence whether the patient should move to a biologic?
Certainly, we would want them to be adherent as the most important thing. Partially because if we're going to be good stewards of care and finances and somebody is not going to take their basic medicine and they're going to switch to a medicine that's $20,000 or $30,000 a year just because they're not taking their inhaler, I have a hard time with that. So, definitely adherence or compliance with their routine medicines should come first. And, in an ideal world, to put them on such an expensive medicine as a biologic just because they won’t take their inhaled steroid is something I would struggle with.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
